Evidence map›Paper›PMID 37887176›Full record

ReviewAntibiotics (Basel, Switzerland)2023

Antibiotics in Chronic Liver Disease and Their Effects on Gut Microbiota.

Nahum Mendez-Sanchez, Carlos Esteban Coronel-Castillo, Jacqueline Cordova-Gallardo, Xingshun Qi

Open access · goldAbstract readReview
In one paragraph

Review in Antibiotics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 2 countries.

Nahum Mendez-SanchezUnit Liver Research, Medica Sur Clinic & Foundation, Mexico City 14050, Mexico.ORCID 0000-0001-5257-8048
Carlos Esteban Coronel-CastilloInternal Medicine Section, Central Military Hospital, Mexico City 11200, Mexico.ORCID 0000-0003-0848-2000
Jacqueline Cordova-GallardoDepartment of Hepatology, Service of Surgery and Obesity Clinic, General Hospital "Dr. Manuel Gea González", Mexico City 14080, Mexico.ORCID 0000-0002-4299-5400
Xingshun QiDepartment of Gastroenterology, General Hospital of Northern Theater Command, Shenyang 110840, China.ORCID 0000-0002-9448-6739
General Hospital of Shenyang Military Region · CNHospital Central Militar · MXHospital General Dr. Manuel Gea Gonzalez · MXHospital Médica Sur · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Impairments in liver function lead to different complications. As chronic liver disease progresses (CLD), hypoalbuminemia and alterations in bile acid compositions lead to changes in gut microbiota and, therefore, in the host-microbiome interaction, leading to a proinflammatory state. Alterations in gut microbiota composition and permeability, known as gut dysbiosis, have important implications in CLD; alterations in the gut-liver axis are a consequence of liver disease, but also a cause of CLD. Furthermore, gut dysbiosis plays an important role in the progression of liver cirrhosis and decompensation, particularly with complications such as hepatic encephalopathy and spontaneous bacterial peritonitis. In relation to this, antibiotics play an important role in treating CLD. While certain antibiotics have specific indications, others have been subjected to continued study to determine whether or not they have a modulatory effect on gut microbiota. In contrast, the rational use of antibiotics is important, not only because of their disrupting effects on gut microbiota, but also in the context of multidrug-resistant organisms. The aim of this review is to illustrate the role of gut microbiota alterations in CLD, the use and impact of antibiotics in liver cirrhosis, and their harmful and beneficial effects.

Indexed as

antibioticsbile acidsdysbiosisgut microbiotainflammationliver cirrhosismetabolic dysfunctionPAMPs

Identifiers

PMID37887176
PMCPMC10603944
OpenAlexW4386962421

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.